Trieza Therapeutics, Inc. logo

Trieza Therapeutics, Inc.

Trieza Therapeutics is a new company developing immunomodulatory oncolytic viruses for the treatment of cancer. Founded as a spin-out from Potenza Therapeutics, Trieza has a portfolio containing multiple pre-clinical candidates.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1030 Massachusetts Avenue Suite 210, MA, 02138
Cambridge
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Trieza Therapeutics, is developing immunomodulatory oncolytic viruses that attack cancer cells.

In Dec 2016, Abzena PLC has granted Trieza an exclusive worldwide, royalty-bearing licence to an undisclosed antibody sequence,
created using Abzenas Composite Human Antibody technology. Under the terms, Abzena will receive up to USD35.0 Mn in development and commercial milestone, plus further royalties on the sale of licensed products.